The burgeoning landscape of novel treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a similar https://bookmarkingalpha.com/story20716547/retatrutide-vs-tirzepatide-a-comparative-analysis